Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.43 |
| ▸ | HPGD | P15428 | 5/20 | 0.43 |
| ▸ | CASP1 | P29466 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | CASP7 | P55210 | 4/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2790760 | 0.83 | DYRK1A (0.59) | CA2DYRK1AALDH1A1KDM4EHSD17B10 | |
| Hydrochloric Acid SCHEMBL2482195 | 0.81 | DYRK1A (0.58) | CA2DYRK1AALDH1A1KDM4EHSD17B10 | |
| Dimethylamine SCHEMBL2103953 | 0.78 | DYRK1A (0.54) | CA2DYRK1AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL806492 | 0.77 | ALDH1A1 (0.50) | DYRK1AALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL9018982 | 0.77 | CA2 (0.55) | CA2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL29384323 | 0.76 | HSD17B3 (0.64) | CA2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL534918 | 0.76 | HSD17B3 (0.64) | CA2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL8155015 | 0.74 | CA12 (0.50) | DYRK1AALDH1A1KDM4EHPGDCA12 | |
| SCHEMBL2269879 | 0.74 | HSD17B3 (0.61) | CA2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL8290256 | 0.74 | APP (0.44) | DYRK1AALDH1A1KDM4EHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3266848-B1 | ORGANIC LIGHT-EMITTING ELEMENT CAPABLE OF LOW-VOLTAGE DRIVE AND HAVING LONG LIFE | SFC CO LTD (KR) | 2019-07-31 | — | — | EP | disclosed |
| US-8026239-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-27 | — | — | US | disclosed |
| US-8026239-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-27 | — | — | US | disclosed |
| US-20100256201-A1 | CELL DIFFERENTIATION INDUCER | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-07 | — | — | US | disclosed |
| US-20100256201-A1 | CELL DIFFERENTIATION INDUCER | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-07 | — | — | US | disclosed |
| US-7687525-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-30 | — | — | US | disclosed |
| US-7687525-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-30 | — | — | US | disclosed |
| US-RE40703-E1 | Cell differentiation inducer, benzamide compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-04-28 | — | — | US | disclosed |
| US-RE40703-E1 | Cell differentiation inducer, benzamide compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-04-28 | — | — | US | disclosed |
| US-20080188489-A1 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-08-07 | — | — | US | disclosed |
| US-7317028-B2 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-01-08 | — | — | US | disclosed |
| US-7317028-B2 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-01-08 | — | — | US | disclosed |
| US-RE39754-E1 | Benzamide derivatives and pharmaceutical compositions containing same | SCHERING AG (DE) | 2007-07-31 | — | — | US | disclosed |
| US-RE39754-E1 | Benzamide derivatives and pharmaceutical compositions containing same | SCHERING AG (DE) | 2007-07-31 | — | — | US | disclosed |
| CN-1191063-C | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | GENENTECH INC (US) | 2005-03-02 | — | — | CN | disclosed |
| US-6544981-B2 | Anticoagulants, cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-08 | — | — | US | disclosed |
| EP-1294716-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | Bristol-Myers Squibb Company (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-28 | — | — | US | disclosed |
| WO-2001096331-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| CN-1295471-A | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | GENENTECH INC (US) | 2001-05-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188489-A1 | Cell differentiation inducer | MCL1, MYADM, MYD88 | CA2 1116/4885DYRK1A 3283/4885ALDH1A1 312/4885 |
| US-20100256201-A1 | CELL DIFFERENTIATION INDUCER | MCL1, MYADM, MYD88 | CA2 1185/4885DYRK1A 3315/4885ALDH1A1 296/4885 |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | F9, F7, F11 | CA2 3830/4885DYRK1A 4096/4885ALDH1A1 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.